Thu, January 26, 2017
Wed, January 25, 2017
Tue, January 24, 2017
Mon, January 23, 2017
Fri, January 20, 2017
Thu, January 19, 2017
Wed, January 18, 2017
Tue, January 17, 2017

Kennen MacKay Initiated (BMRN) at Buy with Decreased Target to $107 on, Jan 23rd, 2017

  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. th-decreased-target-to-107-on-jan-23rd-2017.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Kennen MacKay of Credit Suisse, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $111 to $107 on, Jan 23rd, 2017.

Kennen has made no other calls on BMRN in the last 4 months.



There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 2 agree with Kennen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Downgraded from Buy to Hold and Decreased Target to $105 on, Tuesday, November 29th, 2016
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold on, Monday, November 7th, 2016


This is the rating of the analyst that currently disagrees with Kennen


  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016